Dr. Sebastian B. Heersink, MD

Dr. Heersink practices at Surgery Center South in Dothan, Alabama.

Dr. Heersink's NPI, 1376701391, was assigned on May 27, 2008. Dr. Heersink graduated from Georgetown University School of Medicine in 2007. Dr. Heersink holds Alabama license MD.30827.

Dr. Heersink's primary practice is Surgery Center South, at 2800 Ross Clark Circle, Suite 3, Dothan, AL 36301. The practice phone is (334) 793-3411.

Dr. Heersink's primary practice is Surgery Center South in Dothan, Alabama. Dmand AI also links Dr. Heersink to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Heersink practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Heersink's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dmand AI has Dr. Heersink's licenses on file in 2 states: Alabama and Virginia.

Dmand AI lists cataract, cataract surgery with lens implant, conjunctivitis, eye infection or inflammation, eyelid inflammation, glaucoma, glaucoma surgery and hereditary corneal conditions among the conditions Dr. Heersink treats.

CMS data shows 8,400 Medicare services from Dr. Heersink across 29 procedure codes in 2024, for 1,165 Medicare patients. Medicare paid $993,836 for them.

CMS counts 1,165 Medicare patients who saw Dr. Heersink in 2024. The largest group is 65 to 74, with 624 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.01, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Heersink's median patient age at 71, with 56% women.

In 2024, Dr. Heersink wrote 4,943 Medicare Part D claims for 1,686 patients. 61% of them were for generic drugs. CMS names the drug for 4,832 of them, across 30 drugs with 11 or more claims each, at $639,681 in total drug cost. In 2023, CMS named 4,021 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Heersink for performance year 2024, reported as part of a group. Dr. Heersink accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 1,471 procedures of cataract surgery by Dr. Heersink, more than 99% of the clinicians it reports for that procedure.

Dmand AI links 4 papers to Dr. Heersink, published from 2021 to 2024. 2024 was the busiest year, with 2. Dr. Heersink's most frequent co-authors are John Palmer Berdahl, MD, Andy Matthew Lee, MD and David J. Applegate, DO.

Dmand AI links Dr. Heersink to 3 clinical trials. Conditions studied include Dry Eye Syndromes, Glaucoma, Open-Angle and Presbyopia. Open Payments lists research payments to Dr. Heersink that name 1 trial.

CMS Open Payments shows 547 general payments to Dr. Heersink from 36 drug and device companies from 2016 to 2025. Device or supply loans make up the largest share, 44% of the total. Glaukos Corporation paid the most, $21,163. It also lists 4 research payments totaling $38,368 from 2016 to 2025, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Heersink, most recently CMS Stage 1 EHR in 2013.

Dr. Heersink graduated from Georgetown University School of Medicine in 2007.

Dr. Heersink is in network with 19 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.